Opinion|Videos|April 1, 2024
Treating HCC: Safety Profile Considerations
Tanios S. Bekaii-Saab, MD, discusses safety profile considerations for patients undergoing treatment for hepatocellular carcinoma, and the Oncology Brothers recap the entire discussion.
Advertisement
Advertisement
Related to this article
Lutetium Lu 177 dotatate injection has been approved by the FDA for patients with somatostatin receptor-positive GEP-NETs.
A GDNS protocol did not significantly reduce loss of ASMI compared with usual care during chemoradiotherapy following esophagectomy in esophageal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
4
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
5